Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.65
3.58
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc
Other Long-Term Assets
Lexicon Pharmaceuticals Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
|
Other Long-Term Assets
$828k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
24%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$8.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
44%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$7.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
23%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$10.4B
|
CAGR 3-Years
18%
|
CAGR 5-Years
43%
|
CAGR 10-Years
21%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$3.2B
|
CAGR 3-Years
49%
|
CAGR 5-Years
17%
|
CAGR 10-Years
95%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$4.1B
|
CAGR 3-Years
70%
|
CAGR 5-Years
34%
|
CAGR 10-Years
31%
|
|
Lexicon Pharmaceuticals Inc
Glance View
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 87 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.
See Also
What is Lexicon Pharmaceuticals Inc's Other Long-Term Assets?
Other Long-Term Assets
828k
USD
Based on the financial report for Sep 30, 2024, Lexicon Pharmaceuticals Inc's Other Long-Term Assets amounts to 828k USD.
What is Lexicon Pharmaceuticals Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
24%
Over the last year, the Other Long-Term Assets growth was 18%.
You don't have any saved screeners yet